CG Oncology, Inc. (CGON) Earnings Call Transcripts

CG Oncology, Inc.'s Latest Earnings Call - June 9, 2026

In the Q2 2026 earnings call for CG Oncology, Inc., management highlighted significant progress in their clinical trials, particularly the PIVOT 006 trial, which is set to provide results in the coming months. The company reported a strong cash position of over $1 billion, ensuring operational runway through 2029. While specific revenue and earnings figures were not disclosed, management's focus on upcoming data releases and regulatory filings indicates potential catalysts that could positively influence stock performance in the near term.

Reported metrics

Guidance from management

Management reiterated that they expect to file for BLA in 2027, contingent on the data from the PIVOT 006 trial and ongoing preparations for regulatory requirements.

What management said

Sure. So we're a company that's laser-focused on developing our oncolytic immunotherapy, creative imagine for patients with both intermediate risk as well as high-risk non-muscle invasive bladder cancer. And we have a number of catalysts coming up. Most importantly, we have a Phase III randomized controlled trial called PIVOT 006. Its results will come in the coming months. shortly thereafter, we are guiding to compl...

Sure. So in general, bladder cancer is split into both non-mass invasive bladder cancer, which is about 80% of the opportunity and 20% are in the muscle invasive category of which that contains some metastatic patients. So the bulk of the opportunity is fill in NMIBC. Within NMIBC, we see 70% of that being the target population that we're going after. So that's in the intermediate risk category as well as the high-ri...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape and the need for clear differentiation in the market. There were questions about the adequacy of the clinical data to support pricing strategies and the potential for market uptake given existing therapies.

Main topics on the call

• PIVOT 006 Trial Progress — Management confirmed that the PIVOT 006 trial has completed enrollment ahead of schedule, with 364 patients enrolled by September 2025. Arthur Kuan stated, "the enthusiasm that a lot of physicians have with a novel thera...
• Cash Position and Runway — CG Oncology reported a robust cash position of over $1 billion, providing a financial runway through 2029. This strong balance sheet supports ongoing clinical and commercial activities, as noted by Kuan, "we have about o...
• Clinical Data and Efficacy — Management highlighted a 76% complete response rate for their product in the BCG responsive cohort, with a 42% response rate maintained at 24 months. Kuan emphasized this as a key differentiator, stating, "we think is ca...
• Regulatory Filing Timeline — The company is on track to file for BLA in 2027, with Kuan stating, "we've been guiding that in 2027 is when we could file the BLA." This timeline aligns with the expected data release from the PIVOT 006 trial.

Read the full CG Oncology, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 CG Oncology, Inc. earnings call transcripts on record, spanning May 3, 2024 to June 9, 2026. Based on this history, CG Oncology, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CGON

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

10

First call

May 3, 2024

Most recent

June 9, 2026

Reporting cadence

quarterly